Table 3.
Effect of febuxostat on serial serum uric acid concentrations (mg/dL)
| Baseline | 1 month | 3 months | 6 months | 12 months | |
|---|---|---|---|---|---|
| FN | 8.4±0.3† | 6.2±0.3* | 6.4±0.3* | 6.2±0.3 | 6.1±0.3* |
| FC | 7.5±0.4† | 6.6±0.4 | 7.3±0.2 | 6.4±0.2 | 5.9±0.2* |
| OB | 7.7±0.2† | 7.7±0.3 | 7.7±0.3† | 7.2±0.3 | 7.6±0.4† |
| CT | 6.3±0.3 | 6.9±0.4 | 6.4±0.3 | 6.4±0.4 | 6.4±0.3 |
| NPTHU | 5.6±0.2* | 5.8±0.2* | 5.8±0.2* | 5.7±0.2* | 5.6±0.2* |
Notes: Values are shown as the mean ± standard deviation.
*
P<0.05 versus OB,
†
P<0.05 versus CT.
Abbreviations: FN, newly treated with febuxostat; FC, conversion to febuxostat; OB, observation without intervention; CT, continued conventional therapy; NPTHU, non-post-transplant hyperuricemia.